Section Chief: David Ramirez, M.D.
Our department offers educational opportunities for trainees at all experience levels. Through various programs, department faculty oversee the training of medical and surgical oncology fellows, internal medicine residents and pharmD residents. We also facilitate various observership programs for undergraduate and foreign trainees as well as post-doctoral fellowship training.
Section Chief: Sadia Saleem, M.D.
The Breast Medical Oncology department offers care to patients at MD Anderson's Houston Area Locations, including League City, Sugar Land, West Houston and The Woodlands.
Section Chief: Banu Arun, M.D.
The High-Risk Breast Screening and Genetics Clinic serves patients with increased risk of breast cancer due to a hereditary cancer syndrome, family history and/or personal risk factors. A multidisciplinary team of physicians and genetic counselors work with patients to assess hereditary cancer risk and discuss genetic testing options with the goal of providing individualized cancer screening and prevention recommendations.
Section Chief: Carlos Barcenas, M.D.
The Breast Cancer Survivorship Program focuses on the medical and psychosocial needs of breast cancer survivors. The Breast Cancer Survivorship Clinic works with other disciplines to provide personalized, evidence-based survivorship care plans to improve health, quality of life and clinical outcomes for our cancer patients and their families. Our research focus is on reducing the negative consequences of breast cancer diagnosis and treatment and improving breast cancer long-term outcomes.
The section of Translational Breast Cancer Research (TBCR) is leading the effort to coordinate all stages of the therapeutic and biomarker discovery related to breast cancer. Our initiative is to design new, accurate predictive biomarker and specific systemic treatment with less toxicity. We accelerate the delivery of new therapies from the research bench to the patient’s bedside.
Our goal is to reduce the suffering of breast cancer patients by translation of new discoveries to maximize patient benefit through development of personalized and innovative molecular biomarkers and targeted therapies, based on value-driven translational/clinical research and through nurturing a new generation of oncology investigators.
We strive is to be the world's premier breast cancer translational research section through multidisciplinary and collaborative research.
Close collaboration with our breast medical oncologist and different disciplines such as medicinal chemistry, pharmacology and toxicology, bioinformatics will provide our investigators to be both productive in clinical and translational research. Our core research effort is also supported by conducting investigator initiated clinical trials for both therapeutic, biobanking, and biomarker development in the clinical area.
The section is divided into individual laboratory research group by faculty listed below and our preclinical working group, “Enhanced Drug-Development Guide & Evaluation (EDGE) Preclinical Solutions.” The EDGE Preclinical solutions aim to provide rapid drug development platforms by enhancing the value of novel therapeutic approach and guiding investigator-initiated clinical trials or standard of care. The group is dedicated to discovering and developing targeted therapies and molecular biomarkers for outstanding patient care based on value-driven translational/clinical research through extensive collaboration with industry and academia. For interest for collaboration, please contact Jangsoon (Jason) Lee.
T. Ueno, M.D. Ph.D., F.A.C.P.
Professor & Section Chief
Research Interests: Our research group focused on preclinical development and biomarkers which led to novel clinical trials related to breast cancer. We also conducts numerous investigators initiated clinical trials for an early drug development. In particular, his research area covers inflammatory breast cancer, triple negative breast cancer, and metastatic breast cancer.
Carlos H. Barcenas, M.D., M.Sc.
Research Interests: Barcenas' focus is to decrease breast cancer mortality by validating molecular biomarkers and targeted therapies by conducting clinical trials in breast cancer patients who develop a molecular relapse.
Primary appointment: Leukemia dept.
Joint appointment: Breast Medical Oncology dept.
Research Interests: Battula’s research is focused on targeting cancer stem cells (CSCs), a rare population of cells present in the primary tumor that are drug resistant and cause tumor relapse.
Chandra Bartholomeusz, M.D., Ph.D.
Research Interests: The Bartholomeusz Laboratory is dedicated to conducting research to uncover the mechanisms of triple-negative breast cancer (TNBC) tumorigenesis and metastasis, identify novel TNBC therapeutic targets and ultimately improve the survival of patients with TNBC. Specific targets of interest which are being further investigated include ERK, PEA-15, Mcl-1 and MELK.
Debeb, DVM, Ph.D.
Research Interests: The major goal of the Debeb lab is to identify and target the molecular determinants of brain metastasis, and to understand the molecular mechanisms underlying the unique pathobiology of inflammatory breast cancer (IBC), a very aggressive variant of breast cancer.
Jangsoon Lee, Ph.D.
Research Interests: Jangsoon Lee is an assistant professor and team leader for Enhanced Drug-development Guidance and Evaluation (EDGE) Preclinical Solutions at the Breast Medical Oncology department. Lee’s research focuses on conducting translational studies in HER2, HER3, androgen receptors, HDAC, and cell cycle targeting breast cancer. In addition, Lee is interested in early drug development, exploring the molecular mechanism of spontaneous metastasis and tumorigenicity using humanized breast cancer mouse models. Lee’s key strengths involve developing comprehensive preclinical research via EDGE platforms for translational research in breast cancer to support novel clinical trials.
Xiaoping Wang, Ph.D.
Sr. Research Scientist
Research Interests: Wang's research focuses on the identification of novel therapeutic targets (EGFR, TGF-beta, Axl) and prognostic biomarkers for patients with inflammatory breast cancer (IBC), the most aggressive type of breast cancer and one for which effective targeted therapies are limited.
1155 Pressler Street
5th Floor - CPB5.3450
Houston, TX 77030
1515 Holcombe Blvd., Unit 1354
Houston, TX 77030
- Marcy Sanchez, program coordinator: 713-792-4084
- Larry Coffer, lab manager: 713-563-1512
- Jason Lee, EDGE team leader: 713-563-9221
- Janice Succi, grant coordinator: 713-745-6062
- Ariana Trevino & Jenny Chang, finance: 713-792-2817